Novo Nordisk rises by 5%. According to Berenberg analysts, a forecast upgrade is likely under these conditions.

A strong market launch of the Wegovy pill, combined with potentially increasing sales volumes for injection solutions, fuels analysts' expectations for an imminent raise of the annual targets by Novo Nordisk. The orally formulated weight loss drug, launched in January, accounted for 33% of all Wegovy prescriptions by May. This operational success is further supported by positive analyst sentiments: Berenberg reaffirms the "Buy" rating with a revised price target of 325 DKK, while Nordea upgrades the stock to Buy.   Why a forecast...